Award Number: W81XWH-11-1-0678

TITLE: Preclinical Testing of Novel Oxytocin Receptor Activators in Models of Autism Phenotypes

PRINCIPAL INVESTIGATOR: Cort Pederson, MD

CONTRACTING ORGANIZATION: University of North Carolina at Chapel Hill
Chapel Hill, NC 27599

REPORT DATE: November 2015

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
### Preclinical Testing of Novel Oxytocin Receptor Activators in Models of Autism Phenotypes

**1. REPORT DATE**
November 2015

**2. REPORT TYPE**
Final Report

**3. DATES COVERED**
8 AUG 2011 - 7 AUG 2015

**4. TITLE AND SUBTITLE**
Preclinical Testing of Novel Oxytocin Receptor Activators in Models of Autism Phenotypes

**5. AUTHOR(S)**
Dr. Cort Pedersen
Co-PIs: Michael B. Jarstfer, PhD. and Dr. Sheryl S. Moy

E-Mail: Cort_Pedersen@med.unc.edu

**6. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
HAMILTON BROWN
104 AIRPORT DR STE 2200
CHAPEL HILL NC 27599-5023

**7. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**

**8. SPONSOR/MONITOR'S ACRONYM(S)**
USAMRMC

**9. SPONSOR/MONITOR'S REPORT NUMBER(S)**

**10. DISTRIBUTION / AVAILABILITY STATEMENT**
Approved for Public Release; Distribution Unlimited

**11. SUPPLEMENTARY NOTES**
Please note that this annual report is for a project with three principal investigators: Michael Jarstfer, Cort Pedersen, and Sheryl Moy.

**12. ABSTRACT**
Currently, there are no established pharmaceutical strategies that effectively treat core autism spectrum disorder (ASD) symptoms, including pervasive social deficits and repetitive behaviors. The oxytocin pathway has an important role in normal human social behaviors, and oxytocin dysregulation has been implicated in ASD-associated behavioral symptoms. There is now emerging evidence that oxytocin has therapeutic efficacy in ameliorating core ASD symptoms associated with social behavior. However, from the standpoint of drug discovery, oxytocin is a poor candidate as a standard clinical treatment. Oxytocin is rapidly metabolized and has low brain penetrance with peripheral administration. The goal of the proposed studies is to discover new small-molecule compounds that enhance oxytocin signaling, as novel drug interventions for social deficits and abnormal repetitive behavior relevant to ASD. In this third year, we have extended our published findings that oxytocin can effectively overcome representative ASD phenotypes in two mouse lines that model ASD-like behaviors, including overt alterations in social behavior, and we have confirmed these effects in a genetic model of social impairment, the Grin1 knockdown mouse. We have also evaluated one synthetic oxytocin agonist, Compound 39, and one oxytocin metabolite, for efficacy against social deficits in BALB/cByJ mice, and we are currently evaluating a second oxytocin metabolite for prosocial effects. Overall, we have successfully validated three mouse models as preclinical screens for compounds targeting the oxytocin receptor, and provided leads for a drug discovery campaign for social deficits and other core autism symptoms.

**13. SUBJECT TERMS**
autism, mouse model, neuropeptides, oxytocin, sociability

**14. SECURITY CLASSIFICATION OF:**

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>b. ABSTRACT</th>
<th>c. THIS PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
</tbody>
</table>

**15. SECURITY CLASSIFICATION OF ABSTRACT**: U

**16. NUMBER OF PAGES**: 31

**17. LIMITATION OF ABSTRACT**: U

**18. TELEPHONE NUMBER**

<table>
<thead>
<tr>
<th>a. NAME OF RESPONSIBLE PERSON</th>
<th>b. TELEPHONE NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>USAMRMC</td>
<td>(include area code)</td>
</tr>
</tbody>
</table>
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>5</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>14</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>14</td>
</tr>
<tr>
<td>Conclusion</td>
<td>14</td>
</tr>
<tr>
<td>References</td>
<td>16</td>
</tr>
<tr>
<td>Appendix I (Statement of Work)</td>
<td>17</td>
</tr>
<tr>
<td>Appendix II (Meeting Abstracts and Publication)</td>
<td>20</td>
</tr>
<tr>
<td>List of Personnel</td>
<td>21</td>
</tr>
</tbody>
</table>
Introduction

Currently, there are no established pharmaceutical strategies that effectively treat core autism spectrum disorder (ASD) symptoms, including pervasive social deficits and repetitive behaviors. The oxytocin pathway has an important role in normal human social behaviors, and oxytocin dysregulation has been implicated in ASD-associated behavioral symptoms. There is now emerging evidence that oxytocin has therapeutic efficacy in ameliorating core ASD symptoms associated with social behavior. However, from the standpoint of drug discovery, oxytocin is a poor candidate as a standard clinical treatment. Oxytocin is rapidly metabolized and has low brain penetrance with peripheral administration. The goal of this project was to discover new small-molecule compounds that enhance oxytocin signaling, as novel drug interventions for social deficits and abnormal repetitive behavior relevant to ASD. By the completion of the studies, we had established that oxytocin can effectively overcome representative ASD phenotypes in three mouse lines that model ASD-like behaviors, including overt alterations in social behavior and abnormal repetitive behavior. Our approach was to, first, prioritize synthetic compounds that activate the oxytocin receptor using cell-based assays, and secondly, evaluate the therapeutic efficacy of the top molecules in the characterized mouse lines (compound 39, carbetocin, and the oxytocin derivatives OT(4-9) and OT(5-9)). Our research employed a highly-innovative screening paradigm to identify activators of oxytocin function relevant to treatment strategies for ASD. Overall, our findings have supported the oxytocin pathway as a drug target for the amelioration of ASD-associated phenotypes, contributed to the drug discovery process by establishing mouse models for preclinical testing, and provided leads for a drug discovery campaign directed at the oxytocin receptor.
Body

Validation of mouse models as preclinical efficacy screens. We have previously observed low sociability in adolescent mice from the BALB/cByJ (Moy et al, 2007) and C58/J (Moy et al, 2008; Ryan et al, 2010) inbred strains and in the Grin1 knockdown mouse (Duncan et al. 2004; Moy et al. 2012). In year two of this DoD award, we published a manuscript reporting that the lack of social preference in both the BALB/cByJ and C58/J models can be reversed by a 2-week chronic regimen of oxytocin (1.0 mg/kg) treatment (Teng et al, 2013), whereas a single dose of oxytocin was ineffective. Our findings are the first evidence that the two inbred strain models can be utilized as preclinical screens for prosocial effects of novel compounds active at the oxytocin receptor. A particularly intriguing aspect of our findings in the BALB/cByJ mice is that prosocial effects of oxytocin can be observed 24 hours after the final oxytocin treatment. More recently, we have determined that enhanced sociability is still strongly present 48 hours following oxytocin treatment (Figure 1). These new findings provide an important confirmation of prosocial oxytocin effects in the BALB/cByJ model, and also provide evidence for a marked persistence of enhanced social approach by subchronic oxytocin treatment.

Figure 1. Prosocial effects of oxytocin 48 hr after final treatment in BALB/cByJ. Subjects were tested for sociability in a 3-chamber choice task. The subchronic regimen consisted of four treatments with either vehicle or oxytocin (1.0 mg/kg, IP) across an 8-9 day period. Data are means (+SEM) for 8 male mice per treatment group. *p<0.05, within-group comparison to empty cage side. #p<0.05, comparison to vehicle-treated group.

We also investigated whether oxytocin would exert prosocial effects in adult C58/J mice, similar to our findings in adolescents. Motivation for social affiliation and regulation of social interactions can differ between adolescents and adults. In particular, adolescents have greater sensitivity to the rewarding aspects of novel social stimuli, suggesting the possibility that oxytocin might be most effective at this stage of development, while long-term social deficits in adult mice could be more recalcitrant to reversal. We found that both male and female adult C58/J mice (ages 5-6 months) treated with oxytocin, but not vehicle, had significant preference for the stranger side of a 3-chamber box (Figure 2). In the male mice, the prosocial oxytocin effects were evident at 24 hr and 2 wk post-
treatment (Figure 1a, b). Female mice treated with oxytocin demonstrated significant preference for the stranger side only at the 24 hour time point (Figure 1c). Thus, enhanced social approach following oxytocin can be observed in adult mice, as well as adolescents.

![Bar graphs showing time in side for males and females at 24 hours and 2 weeks](image)

**Figure 2. Persistent prosocial effects of subchronic oxytocin in adult C58/J mice.** Subjects were tested for sociability in a 3-chamber choice task. The subchronic regimen consisted of 4 treatments with either vehicle or oxytocin (1.0 mg/kg, IP) across an 8-9 day period. Mice were tested at 24 hr, and again at 2 wk, following the final treatment. *p<0.05, within-group comparison to empty cage side.

This study suggested female C58/J mice were less sensitive to the prosocial effects of oxytocin. Therefore, we tested a separate set of female C58/J mice, using a subchronic treatment regimen with 2 mg/kg oxytocin, in order to see if persistent prosocial effects would be observed with a higher dose. In addition, we extended the testing to 4 weeks after the end of the treatment regimen. On the day following each social test (at 24 hr, 2 weeks, and 4 weeks after the last injection), mice were further evaluated in an observational screen for abnormal repetitive behavior. As shown in Figure 3, the higher dose of oxytocin led to increased sociability at both 2 weeks and 4 weeks following the subchronic regimen. However, as we previously reported for the lower oxytocin dose (Teng et al. 2013), the subchronic treatment had no effects on abnormal repetitive behavior in the C58/J model (Figure 4).
Figure 3. Prosocial effects 2 and 4 weeks following subchronic oxytocin. C58/J female mice were given a subchronic regimen with 2.0 mg/kg oxytocin, and tested in a 3-chamber assay at 3 time points (24 hr, 2 weeks, and 4 weeks) following the final injection. N=8 mice per treatment group. *p<0.05, within-treatment comparison to the empty cage side.

Figure 4. Lack of effects of subchronic oxytocin on abnormal repetitive behavior. C58/J female mice were given a subchronic regimen with 2.0 mg/kg oxytocin, and tested in an observational screen at 3 time points (24 hr, 2 weeks, and 4 weeks) following the final injection. N=8 mice per treatment group.
Figure 5. Prosocial effects of subchronic oxytocin in Grin1<sup>neo/neo</sup> mice. Subjects were tested for sociability in a 3-chamber choice task. The subchronic regimen consisted of 4 treatments with either vehicle or oxytocin (1.0 mg/kg, IP) across an 8-9 day period. Grin1 mice were tested 24 hr following the final treatment. N=8-9 mice per treatment group. *p<0.05, within-group comparison to empty cage side. #p<0.05, comparison to vehicle-treated group (Panel A).

In this project, we also proposed to evaluate a genetic mouse model of autism-like phenotypes, the Grin1 knockdown mouse. Although the mechanistic basis for ASD is not known, genetic analyses in human populations have implicated several genes important for synaptic function, including GRIN1, which encodes the obligatory NMDAR1 subunit of the N-methyl-D-aspartate (NMDA) receptor. Mice with reduced Grin1 expression recapitulate many ASD features, including overt social deficits, inappropriate social interaction, abnormal repetitive behavior, self-injurious responses, and impaired sensorimotor gating. In this project, we have found that subchronic oxytocin can induce a striking
increase in sociability in male $\text{Grin}^1\text{neo/neo}$ mice, with no effects in wild-type controls (Figure 5). As shown in Figure 5A, only the $\text{Grin}1$ knockdown mice treated with oxytocin had significant social preference 24 hr following the final injection. In contrast, male $\text{Grin}1^{+/+}$ mice had similar positive sociability after either the vehicle or oxytocin regimen (Figure 5B). No significant effects of genotype or treatment on social approach were observed in the female $\text{Grin}1$ groups (data not shown).

**Prioritization of positive allosteric modulators and agonists.** We previously completed a high throughput screen of over 300,000 compounds in order to identify compounds that activate the oxytocin receptor. All initial positive agonists (199 compounds) and allosteric modulators (65 compounds) have been confirmed using fluorescence-based assays. Overall, most agonists were moderately potent ($EC_{50}$ ranged from 5 to 100 $\mu$M). However, agonists displayed little selectivity for the oxytocin receptor when compared to vasopressin receptors. These results were validated with Ca$^{2+}$ release assays as well as IP$_3$ formation assays (data not shown). We have examined several series of analogs based on active hits, but have not achieved increased specificity. To further our efforts towards new oxytocin (OT) receptor agonists, we examined several oxytocin fragments expected to be metabolites of oxytocin, which we consider derivatives of an active hit from the high throughput screen per Task 5. In year two we reported that these fragments do not have activity against human orphan receptors. We have now tested these OT derivatives against the OT receptor using a “Tango” assay. Surprisingly, even though OT(4—9) exhibited OT activity in vivo, it did not demonstrate OT activity in this cell based assay.

Allosteric modulators, which are more desirable, were generally less potent with maximum increase in response to oxytocin typically about 10 percent. In order to optimize potency, we have continued exploring analoging of derivatives in order to optimize their activity. To date, we have screened 69 analogs of three initial hits (a functionalized amino acid, a pyrazolopyrimidine, and a triazole) in the positive allosteric modulator assay. In year three, we assayed the triazole analogs (Figure 6). The data revealed that even at high concentrations, unfortunately analogs of these three initial hits are not potent enough to warrant further analysis.
Plans for prioritization of positive allosteric modulators and agonists. In the three years of the award, we examined analogs from ten hits from our initial screen. We have determined that PAM design will require an alternative approach and agonist develop will focus on the OT derivatives and synthetic functional selective agonists.

Figure 6. Analysis of positive allosteric modulators of the human oxytocin receptor. Three series of analogs based on initial hits from our high throughput screen for positive allosteric modulation of the human oxytocin receptor have been analyzed. (A) Amino acid derivatives tested in year one. (B) Pyrazolopyrimidine derivatives tested in year two. (C) Triazoles substituted with heteroaromatic rings were tested in year three. Example dose response for the triazole derivatives, the parent compound, in an allosteric modulator assay. The data did not fit to the Hill equation. In short, CHO cells stably transfected with the oxytocin receptor were treated with test compound and 1 nM oxytocin and the oxytocin receptor response was detected by calcium accumulation. Triplicate data were fit by nonlinear regression.

Figure 7. Persistent prosocial effects of oxytocin fragment (4-9) in BALB/cByJ. Vehicle or oxytocin (4-9) was administered across an 8-9 day period. Subjects given 2 tests in a three-chambered choice task, one 24 hours and one 12 days following the final dose. There were no significant effects of treatment or side on entries during either test. N=8 male, adolescent mice per group. *p<0.05, within-treatment comparison.

Establish the effects of OT(4-9) on the behavior of ASD-model mice.
In the Year 2 report, we showed that subchronic treatment regimens with either the higher or lower dose of Compound 39, a synthetic oxytocin agonist, failed to rescue social deficits in the BALB mice (not shown). However, we observed that subchronic treatment with the oxytocin (4-9) metabolite led to significant increases in social preference (Figure 7), suggesting that fragments of the oxytocin nonapeptide might have full prosocial potency. In Year 3 report, we focused much of our attention on OT(4-9) as it represents a new chemical entity with pro-social effects. We confirmed that OT(4-9) exhibits dose-dependent and persistent prosocial effects in BALB mice (Figure 7).

Figure 8. Lack of carbetocin effects following acute or subchronic treatment in BALB/cByJ. A) Mice were tested in a marble-burying assay, with one week between each test. Order of dose was balanced across weeks. Data are means (+ SEM) of 7-18 mice per dose. B) Mice were tested in a 3-chamber social approach assay. Test 1 was conducted 24 hours and Test 2 conducted 11-12 days following the final treatment of a subchronic regimen. Data are means (+ SEM) of 12 vehicle-treated mice and 12 carbetocin-treated mice at each dose (a total of 72 mice).

Preclinical screen of carbetocin, an oxytocin analog. Previous work has shown that peripheral (i.p.) administration of the oxytocin analog, carbetocin, can have anxiolytic and antidepressant-like effects in rodent models (Chaviaras et al. 2010; Klenerova et al. 2010; Zanos et al. 2014), although not all reports have been consistent (Feifel et al. 2011; Mak et al. 2012). For this project, we investigated effects of carbetocin in the BALB/cByJ model, using the marble-burying and 3-chamber social approach tests. As shown in Figure 8, the acute administration of carbetocin, across a range of doses (3 to 20 mg/kg), did not lead to any changes in number of buried marbles. Further, subchronic regimens with either 6, 10, or 20 mg/kg carbetocin failed to enhance sociability in BALB/cByJ mice, tested 24 hours or 11-12 days following the end of treatment. Thus, the set of acute and subchronic regimens and test procedures in our studies have identified four different response profiles of OT and related ligands we studied (Table):

Table Summary of Test Compounds*
<table>
<thead>
<tr>
<th>Ligand</th>
<th>OTR(agonist EC$<em>{50}$); (antagonist Ki or IC$</em>{50}$)</th>
<th>OTR bias$^b$</th>
<th>Phenotype in social approach assay</th>
<th>Other phenotypes</th>
<th>Other Receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytocin</td>
<td>Gq (0.2 nM), β-arrestin</td>
<td>None</td>
<td>Persistent sociability</td>
<td>Reduced stereotypy and marble burying</td>
<td>V1a (EC$_{50}$ 20 nM)</td>
</tr>
<tr>
<td>OT(4-9) pGlu-Asn-Cyt-Pro-Leu-Gly-NH$_2$</td>
<td>No activity (preliminary)</td>
<td>TBD</td>
<td>Persistent sociability</td>
<td>No effect on marble burying</td>
<td>TBD</td>
</tr>
<tr>
<td>OT(5-9) Asn-Cyt-Pro-Leu-Gly-NH$_2$</td>
<td>No activity (preliminary)</td>
<td>TBD</td>
<td>No effect (preliminary)</td>
<td>TBD</td>
<td>TBD</td>
</tr>
<tr>
<td>Carbetocin</td>
<td>Gq, partial β-arrestin (β = -1.55)</td>
<td>Gq bias (β = -0.33)</td>
<td>No effect</td>
<td>No effect</td>
<td>V1a</td>
</tr>
<tr>
<td>SynOTA (Compound 39)</td>
<td>Gq (180 nM), partial β-arrestin</td>
<td>Gq bias (β = -0.33)</td>
<td>No effect</td>
<td>Reduced marble burying</td>
<td>V1b (EC$<em>{50}$, 4,300 nM) D2 (EC$</em>{50}$ &gt; 10 μM)</td>
</tr>
</tbody>
</table>

$^a$Source and quality control of compounds: OT metabolites were synthesized by (Biomatik). $^b$Biased pathway activation of specific OTR pathways by ligands, for example greater activity signaling through Gq than β-arrestin recruitment.

Figure 9. Effects of oxytocin (1 mg/kg) and the oxytocin (4-9) fragment on open field activity and exploration. Data are means (± SEM) for three 2-hr tests, with one week between each test. N=9 BALB/cByJ male mice. *p<0.05, comparison between oxytocin and vehicle.

**Effects of oxytocin and OT (4-9) on open field activity in BALB/cByJ.** We have previously reported that acute oxytocin (1 mg/kg) does not alter locomotor activity in C58/J mice (Teng et al. 2013). More recently, we investigated the effect of acute treatment with the same dose in BALB/cByJ. Mice were injected immediately before placement into open field chambers. The results showed that oxytocin decreased activity across the 2-hour test [repeated measures ANOVA, main effect of treatment, F(2,16)=37.9, p<0.0001] (Figure 9). This same highly significant main effect of oxytocin was observed for time in the center region [F(2,16)=40.13, p<0.0001]. In contrast, OT (4-9), at a dose with prosocial efficacy in a subchronic regimen, had no significant effects on activity or exploration in
the open field, confirming previous findings on a lack of effects in the marble-burying task from acute administration.

**Effects of OT (4-9) on repetitive behavior and open field activity in C58/J.** We have previously found that acute treatment with oxytocin can significantly attenuate abnormal repetitive behavior in C58/J mice (Teng et al. 2013). However, as shown in Figure 10, acute administration of OT(4-9) failed to reduce back-flipping or repeated jumping in C58/J. Further, OT(4-9) had no effects on locomotor activity during the repetitive behavior observational screen, or in a 2-hour open field test.

![Figure 10](image-url)

**Figure 10.** Lack of acute OT(4-9) effects in an observational screen or an open field test. A) Data are means (+ SEM) for a 10-min test, with 10-11 C58/J mice per treatment group. B) Data are means (± SEM) for three 2-hr tests, with one week between each test, for 12 C58/J mice.
Key Research Accomplishments

1. Confirmed that subchronic oxytocin treatment has persistent prosocial efficacy in the BALB/cByJ mouse model.

2. Established that subchronic oxytocin treatment has persistent prosocial efficacy in adolescent and adult C58/J mice, and that acute oxytocin can decrease abnormal repetitive behavior in the model.

3. Established that subchronic oxytocin treatment also has highly significant prosocial effects in Grin1 knockdown mice, a genetic model of synaptic dysfunction relevant to autism.

4. Evaluated derivatives of initial positive allosteric modulator hit in cell-based assays.

5. Characterized OT(4-9), OT(5-9), Compound 39, and carbetocin effects in the BALB/cByJ mouse model. Determined OT(4-9) effects on abnormal repetitive behavior and hyperactivity in the C58/J model. Investigated effects of one dose of OT(4-9) on social approach in the Grin1 model.

6. Key accomplishments in relationship to proposed Statement of Work: we have completed subtasks 1a, 1b, 1c, 1d., 2a, 2b, 2c,2d, 3a, 3b, 3c, 3d (one published manuscript and another is under revision for re-submission), 4a, 4b, initiated 5a, 5b, and completed 6a, 6b, 6d, and 6e (see appendix for proposed Statement of Work).

Reportable Outcomes

1. The research team, including Dr. Brian Teng, the post-doctoral fellow recruited for this project, have published a manuscript on the validation of two mouse models as screens for oxytocin effects on social deficits and repetitive behavior (Appendix II).

2. The results of the our research, including the synthetic oxytocin receptor agonist Compound 39, were presented at the International Meeting for Autism Research May 2-4, 2013. The full abstract is in Appendix II.

3. A proposal entitled “Mechanism for Prosocial Efficacy of Oxytocin and Small-Molecule Analogues” was submitted to the NIH, June 2015.

Conclusion

The goal of this project was to discover new small-molecule compounds that enhance oxytocin signaling, as novel drug interventions for social deficits and abnormal repetitive behavior relevant to ASD. We have demonstrated that a subchronic oxytocin regimen can lead to persistent enhancement of sociability across three mouse models with divergent genotypes and behavioral profiles, suggesting
the possibility of generalized therapeutic benefits across the autism spectrum disorders, as well as other neurodevelopmental disorders characterized by social impairment. We have evaluated two synthetic oxytocin agonists, Compound 39 and carbetocin, and two oxytocin metabolites OT(4-9) and OT(5-9), for efficacy against social deficits in BALB/cByJ mice. Overall, we have successfully validated three mouse models as preclinical screens for compounds targeting the oxytocin receptor, and provided leads for a drug discovery campaign for social deficits and other core autism symptoms. Remarkably, we showed that chronic treatment with either oxytocin or OT(4-9) was required to promote prosocial activity. This is an important observation that will inform both preclinical screening, as well as clinical trials. Prosocial effects were persistent for up to 12 days in BALB/cByJ mice, and up to four weeks following treatment in the C58/J mice. The results with the mouse models indicate that oxytocin and OT(4-9) treatment results in molecular changes that are more complex and long lasting than simply activating the oxytocin receptor. We are currently seeking NIH funding to continue using this panel of models to identify common abnormalities in signaling pathways underlying deficits in social approach, as well as the mechanism of action for adaptive changes in brain with subchronic oxytocin and OT (4-9) treatment.
References


Appendix I
Statement of Work

NOTE: There is one animal site for all experiments: the Mouse Behavioral Phenotyping Laboratory, the corresponding PI is Sheryl Moy, though each PI will participate in experimental design and data interpretation.

**Task 1.** Establish the effect of oxytocin on the behavior of Grin1\(^{neo/neo}\) mice (Major contribution from Drs. Moy and Pedersen, minor contribution from Dr Jarstfer). **Performance site: UNC Chapel Hill, Mouse Behavioral Phenotyping Laboratory, Medical Biomolecular Research Building.**

- **Number of mice:** 183
  - **Subtask 1a.** Submit forms for IACUC approval of animal studies (month 1).
  - **Subtask 1b.** Submit ACURO Animal Use Appendix for Research Involving Animals documents for review and approval of animal studies (months 1-4).
  - **Subtask 1c.** Rear and genotype Grin1\(^{neo/neo}\) mice and wild type controls (months 4-36).
  - **Subtask 1d.** Test the effect of oxytocin on the behavior of Grin1\(^{neo/neo}\) mice in the social approach test (months 6-12). The social approach test uses an automated apparatus for quantitation of social approach behaviors (as described in Moy et al., *Genes, Brain and Behavior* (2004) 3: 303–314). In short, time spent in each chamber and the number of entries are scored automatically by a system detecting photocell beam breaks. We also measure time sniffing and sniffing bouts.

**Task 2.** Establish the effect of oxytocin on the behavior of C58/J mice. (Major contribution from Drs. Moy and Pedersen, minor contribution from Dr Jarstfer). **Performance site: UNC Chapel Hill, Mouse Behavioral Phenotyping Laboratory, Medical Biomolecular Research Building.**

- **Number of mice:** 143
  - **Subtask 2a.** Submit forms for IACUC approval of animal studies (month 1).
  - **Subtask 2b.** Submit ACURO Animal Use Appendix for Research Involving Animals documents for review and approval of animal studies (months 1-4).
  - **Subtask 2c.** Test the effect of oxytocin on the behavior of C58/J mice in the social approach test (months 6-12).
  - **Subtask 2d.** Test the effect of oxytocin on the behavior of C58/J mice in the repetitive behavior test (months 12-18).

**Task 3.** Establish the effect of oxytocin on the behavior of BALB/cByJ mice. (Major contribution from Drs. Moy and Pedersen, minor contribution from Dr Jarstfer). **Performance site: UNC Chapel Hill**
Mouse Behavioral Phenotyping Laboratory, Medical Biomolecular Research Building

Number of mice: 84

Subtask 3a. Submit forms for IACUC approval of animal studies (month 1).
Subtask 3b. Submit ACURO Animal Use Appendix for Research Involving Animals documents for review and approval of animal studies (months 1-4).
Subtask 3c. Test the effect of oxytocin on the behavior of BALB/cByJ mice in the social approach test (months 6-12).
Subtask 3d. Publish findings from tasks 1-3 in scholarly journal.

Task 4. Validate active compounds from the high throughput screen. (Major contribution from Jarstfer). Performance sites: UNC Chapel Hill Genetics Medicine Building (FLIPR assays) and Beard Hall (data analysis and interpretation).

Subtask 4a. Confirm and characterize active agonists from the initial high throughput screen using resynthesized compounds (months 1-4)
Subtask 4b. Confirm and characterize active positive allosteric modulators from the initial high throughput screen using resynthesized compounds (months 2-5)

Task 5. Identify lead compounds for testing in animal models. (Major contribution from Jarstfer). Performance site: UNC Chapel Hill, Genetic Medicine building.

For Task 5, the Specialized Chemistry Center for Accelerated Probe Development will perform synthesis of compounds based on the activity we observe in our cell-based assays. They will perform a service – both intellectually and physically – by making molecules and determining potential derivatives to optimize activity. No cell-based or animal assays will be conducted at the Center. In Task 4, the compounds are the initial hits from the high throughput screen. In Task 5, the compounds are derivatives of the hits, either synthetic or commercially available compounds.

Subtask 5a. Conduct iterative syntheses and testing of agonists in collaboration with the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (months 4-24). We will test between 50 and 200 compounds.
Screening will be conducted using first the cell-based calcium release assay we used in the HTS. Positives will be further analyzed using IP3 release assays. Counter assays using untransfected cells and cells expression the vasopressin receptor will confirm selectivity.
Subtask 5b. Conduct iterative syntheses and testing of positive allosteric modulators in collaboration with the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (months 5-24). We will test between 50 and 200 compounds.
Screening will be conducted using first the cell-based calcium release assay we used in the HTS. Unlike the agonist assay, these assays will include a low level of oxytocin to prime the receptor. Positives will be further analyzed using IP3 release assays. Counter assays using untransfected cells and cells expression the vasopressin receptor will confirm selectivity.

**Subtask 5c.** Analysis of safety and untoward activity of potential test compounds (Months 18-28). Compounds will be screened in cell based assays for activity against other receptors. In particular, assays for bioavailability predictions (CaCo2, MDR-1) and cardiovascular toxicity predictions (HERG, 5-HT2B) will be conducted.

**Subtask 5d.** Publish identification of new oxytocin receptor agonists and positive allosteric modulators.

**Task 6.** Establish the effect of small molecule agonists on the behavior of ASD-model mice (Major contribution from Drs. Moy and Pedersen, minor contribution from Dr Jarstfer). **Performance site:** UNC Chapel Hill Mouse Behavioral Phenotyping Laboratory, Medical Biomolecular Research Building

Agonists will be tested without the addition of oxytocin. Endogenous oxytocin will be present at endogenous levels, but we will not add addition oxytocin.

**Subtask 6a.** Determine appropriate dose of test compounds in C57BL/6J mice using acoustic startle test (months 18-24). NOTE: test changed to marble-burying procedure, based on greater sensitivity to oxytocin effects.

**Subtask 6b.** Test the effect of target compounds on the behavior of Grin1<sup>neo/neo</sup> mice in the social approach test (months 24-36).

**Subtask 6c.** Test the effect of target compounds on the behavior of C58/J mice in the social approach test (months 24-36).

**Subtask 6d.** Test the effect of target compounds on the behavior of C58/J mice in the repetitive behavior test (months 24-36).

**Subtask 6e.** Test the effect of target compounds on the behavior of BALB/cByJ mice in the social approach test (months 24-36).
Appendix II

International Meeting for Autism Research abstract

Mouse Models of Autism Phenotypes As Preclinical Screening Platforms for Novel Oxytocicnergic Compounds

B. L. Teng1,2, R. J. Nonneman1,3, V. D. Nikolova1,4, K. L. Agster1,4, T. T. Davis1,2, N. V. Riddick1,4, L. K. Baker1, C. A. Pedersen1,4, M. B. Jarstfer1,2 and S. S. Moy1,4,

(1) Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC, (2) UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, (3) Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, NC, (4) Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC

Background: There is emerging evidence that oxytocin (OT) treatment can improve social deficits and repetitive behavior in autism spectrum disorders (ASDs). However, administration of the neuropeptide, which has a short plasma half-life and poor ability to penetrate the blood-brain barrier, is a problematic issue for clinical use. We have recently initiated a drug development program to identify novel, highly selective, non-peptide OT receptor (OTR) agonists. These efforts would be accelerated by animal models to screen drug candidates for efficacy against ASD-relevant phenotypes.

Objectives: Validate mouse models for preclinical screening of compounds that target the OT pathway, in order to facilitate the development of therapeutics for core ASD symptoms. Methods: BALB/cByJ and C58/J are well-characterized inbred mouse strains that exhibit behavioral phenotypes relevant to ASD. To validate these models as preclinical screens, mice were tested for OT effects on sociability in a three-chamber task and perseverative responses in a marble-burying assay. C58/J was also examined for OT effects on repetitive behavior and open field activity. These screening platforms were then used to evaluate Compound 39 (a synthetic, non-peptide OTR agonist).

Results: The acute OT regimen did not increase sociability in BALB/cByJ. However, the sub-chronic OT regimen (i.e. four intraperitoneal injections across 7-8 days) had significant prosocial effects in both BALB/cByJ and C58/J. Increased sociability was observed 24 hr following the final OT dose in BALB/cByJ, while prosocial effects of OT emerged 1-2 weeks post-treatment in C58/J. An acute OT regimen decreased motor stereotypy in C58/J, at a dose that did not produce sedative or anxiolytic-like effects in open field testing. Similarly, acute OT treatment led to significant reductions in marble-burying by BALB/cByJ. Consistent with previous research, Compound 39 produced some OT-like effects; however, the drug had no effect on sociability.

Conclusions: These studies show that OT reverses social deficits in mouse models of ASD, dependent on dose regimen and genotype. Furthermore, acute OT decreases abnormal repetitive behavior in C58/J and marble-burying in BALB/cByJ. These findings provide validation of the BALB/cByJ and C58/J models as valuable platforms for screening novel drugs for intervention in ASDs, and for elucidating the mechanisms contributing to prosocial and other beneficial effects of OT.
Publications and abstracts from work.


List of Personnel
Cort Pedersen
Prosocial effects of oxytocin in two mouse models of autism spectrum disorders

Brian L. Teng a,d, *, Randal J. Nonneman a,c, Kara L. Agster a,b, Viktoryia D. Nikolova a,b, Tamara T. Davis a,d, Natallia V. Riddick a,b, Lorinda K. Baker a, Cort A. Pedersen a,b, Michael B. Jarstfer a,d, Sheryl S. Moy a,b

a Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
b Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
c UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
d Division of Chemical Biology and Medicinal Chemistry, University of North Carolina, 308 Beard Hall, Campus Box 7568, Chapel Hill, NC 27599-7568, USA

Abstract

Clinical evidence suggests that oxytocin treatment improves social deficits and repetitive behavior in autism spectrum disorders (ASDs). However, the neuropeptide has a short plasma half-life and poor ability to penetrate the blood–brain barrier. In order to facilitate the development of more bioavailable oxytocinergic compounds as therapeutics to treat core ASD symptoms, small animal models must be validated for preclinical screens. This study examined the preclinical utility of two inbred mouse strains, BALB/cByJ and C58/J, that exhibit phenotypes relevant to core ASD symptoms. Mice from both strains were intraperitoneally administered oxytocin, using either acute or sub-chronic regimens. Acute oxytocin did not increase sociability in BALB/cByJ; however, sub-chronic oxytocin had significant prosocial effects in both BALB/cByJ and C58/J: increased sociability was observed 24 h following the final oxytocin dose in BALB/cByJ, while prosocial effects of oxytocin emerged 1–2 weeks post-treatment in C58/J. Furthermore, acute oxytocin decreased motor stereotypy in C58/J and did not induce hypoactivity or anxiolytic-like effects in an open field test. This study demonstrates that oxytocin administration can attenuate social deficits and repetitive behavior in mouse models of ASD, dependent on dose regimen and genotype. These findings provide validation of the BALB/cByJ and C58/J models as useful platforms for screening novel drugs for intervention in ASDs and for elucidating the mechanisms contributing to the prosocial effects of oxytocin.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Autism spectrum disorders (ASDs), which occur in approximately 1% of the population, are characterized by core deficits in sociability and communication skills, as well as abnormal restrictive and repetitive behaviors (CDC, 2012; Elsabbagh et al., 2012; Nazeer and Ghaziuddin, 2012). Although clinical evidence suggests that some medications may alleviate repetitive behavior in ASDs (e.g. atypical antipsychotics and selective serotonin reuptake inhibitors), these drugs have not proven to be consistently effective and have been associated with significant adverse side effects (Carrasco et al., 2012; McDougle et al., 2005; McPheeters et al., 2011; Stachnik and Nunn-Thompson, 2007). Furthermore, there are no pharmacological interventions for treating the social deficits associated with ASDs; however, the oxytocin signaling pathway is emerging as a promising avenue for ASD drug discovery efforts (Meyer-Lindenberg et al., 2011; Strieppens et al., 2011).

Oxytocin is a neuropeptide hormone with a long recognized role in maternal responses, but there is increasing evidence that oxytocin mediates other aspects of social behavior, and that disruption of normal oxytocin function could lead to impaired sociability and affiliative interactions (Insel, 2010). In line with this premise, several reports indicate oxytocin signaling may be deficient in ASDs (Higashida et al., 2012; Strieppens et al., 2011). Thus, pharmacological activation of central oxytocin receptors could have beneficial effects on core ASD symptoms, especially social deficits. This hypothesis is supported by studies that demonstrate acute high doses of oxytocin can improve social function and reduce repetitive behavior in individuals with ASD (Andari et al., 2010; Stachnik et al., 2011; Stachnik and Nunn-Thompson, 2007). Furthermore, there are no pharmacological interventions for treating the social deficits associated with ASDs; however, the oxytocin signaling pathway is emerging as a promising avenue for ASD drug discovery efforts (Meyer-Lindenberg et al., 2011; Strieppens et al., 2011).
Guastella et al., 2010; Hollander et al., 2007, 2003). However, the clinical utility of oxytocin is limited by its short half-life, poor ability to cross the blood–brain barrier, and affinity for vasopressin receptors (Chini and Manning, 2007; Kang and Park, 2000; Morin et al., 2008; Schorscher-Petcu et al., 2010). These concerns underscore the need to explore the development of selective, non-peptide drugs to target the oxytocin pathway. To achieve this goal, appropriate small animal models are critical for preclinical efficacy testing of novel oxytocinergic compounds.

Previously, we screened multiple commercially-available inbred mouse strains for abnormal phenotypes relevant to core symptoms of human developmental disorders, and identified strains that could serve as appropriate behavioral models for ASDs (Moy et al., 2004, 2008, 2007). For example, we found that specific strains have deficient sociability in a three-chambered choice task, which measures the time a test mouse spends in proximity to a stranger mouse versus an empty cage (i.e. non-social object) (Moy et al., 2008, 2007; Nadler et al., 2004). One of these strains, BALB/cByJ, exhibited both a lack of social preference and high levels of anxiety-like behavior, which could reflect the comorbid anxiety frequently observed in ASDs (Brodkin, 2007). BALB/cJ, a related sub-strain, also has impaired sociability in a three-chambered choice task (Brodkin et al., 2004; Sankoorikal et al., 2006), as well as deficient ultrasonic vocalization during social interaction, which may be relevant to core communication deficits observed in ASDs (Kikusui et al., 2011; Panksepp et al., 2007).

C58/J is another inbred mouse strain that shows low sociability in the three-chambered choice task (Moy et al., 2008; Ryan et al., 2010). C58/J mice also have deficits in social transmission of food preference, a test used to model social communication, and exhibit overt, abnormal repetitive behavior (Ryan et al., 2010). At an early age, C58/J mice spontaneously develop motor stereotypies, which include backflipping, “jackhammer” jumping, and upright scratching (Ryan et al., 2010). These robust ASD-like phenotypes in social and repetitive behaviors make the C58/J strain an attractive model for the preclinical evaluation of drug candidates to treat autism. Thus far, one study has identified an agent (GRN-529, a negative allosteric modulator of the metabotropic glutamate receptor subtype 5) that has efficacy in reducing the repetitive behavior of C58/J mice, but the study did not examine drug effects on the lack of sociability in this strain (Silverman et al., 2012b).

Overall, the oxytocin receptor is among the most promising targets for intervention in ASDs, which highlights the need for translational models to assess the behavioral pharmacology of therapeutics targeting the oxytocin pathway (including oxytocin itself). In the present studies, we utilized BALB/cByJ and C58/J to evaluate the effects of oxytocin treatment on behavioral phenotypes relevant to core ASD symptoms. Using both inbred strains allowed the identification of prosocial oxytocin effects that were dependent on genetic background, and the ability to investigate oxytocin efficacy against aberrant repetitive behavior in C58/J.

2. Methods and materials

2.1. Animals

For the BALB/cByJ model, cohorts of male mice (3–4 weeks old, n = 12–24) were obtained from Jackson Laboratory (JAX; Bar Harbor, ME). For the C58/J model, mice were offspring of C58/J breeding pairs (JAX) weaned at postnatal day 21 and caged with same-sex littermates. Dams were fed ProLab RMH 2000 and all other mice were fed ProLab RMH 3000 ad libitum with free access to water. Mice were maintained in groups of 2–4 animals per polycarbonate mouse cage lined with Bed-o-Cobs bedding. For enrichment, each cage contained a small section of PVC pipe and two nestlet squares. Mice were housed in an animal facility at The University of North Carolina at Chapel Hill (UNC) in a room with a 12-h light/dark cycle (lights off at 7 pm). All animal care and procedures were conducted in strict compliance with the animal welfare policies set by the National Institutes of Health and UNC, and were approved by the UNC Institutional Animal Care and Use Committee.

2.2. Drug treatment

Oxytocin (Bachem, Torrance, CA) was dissolved in saline containing 0.002% acetic acid. For acute treatments, mice were given a single intraperitoneal (IP) injection of vehicle or 1.0 mg/kg oxytocin 50 min prior to testing for sociability (BALB/cByJ model; Fig. 1), or for repetitive behavior (C58/J model). For sub-chronic treatments (both models), mice were given four IP injections of vehicle or 1.0 mg/kg oxytocin across 8–9 days, with at least 48 h between each injection; behavioral tests

![Fig. 1](image-url). Experimental timelines for the acute and sub-chronic oxytocin regimens, and behavioral tests in BALB/cByJ and C58/J mice. The acute regimen was a single-dose of vehicle or oxytocin (1.0 mg/kg) administered 50 min before behavioral testing. The sub-chronic regimen consisted of four doses of either vehicle or oxytocin (1.0 mg/kg) across an 8–9 day period, with at least 48 h between each IP injection. Sociability (Social) or repetitive (Rep.) behavior testing occurred on the indicated days. C58/J Cohorts 3 and 4 are not shown.
occurred approximately 24 h after the last injection (Fig. 1). This sub-chronic regimen was designed to reduce the stress that might be found with daily injections, while enhancing sensitivity to oxytocin, as observed with other drugs (Fiorino and Philips, 1999; Moy and Breese, 2002). Considering the pharmacokinetic properties of oxytocin, many groups have used intracerebroventricular (ICV) injections for acute oxytocin treatments; however, this route induces significant stress and sometimes requires anesthesia in mice, which could interact with oxytocin effects and would not be ideal for repeated administration (Kim et al., 1998; Yamakage et al., 2002). The IP route of administration was selected for rapid drug absorption and relatively minimal stress for the animals. Importantly, other groups have shown that acute IP injection of 1.0 mg/kg oxytocin in mice has antidepressant-like, anti-nociceptive, and autonomic nervous system effects, suggesting that oxytocin is able to enter the central nervous system by this method (Arletti and Bertolini, 1987; Lundeberg et al., 1994; Ring et al., 2006). Experimenters blind to drug identity performed all injections and behavioral tests during daytime (light phase) hours (10 am–4 pm).

2.3. Behavioral tests

2.3.1. BALB/cByJ model

Effects of acute and sub-chronic oxytocin on social preference in the three-chambered choice task were evaluated in separate cohorts of male mice, 6–7 weeks of age at time of testing. The study focused on male mice, in accordance with the higher incidence of autism observed in male versus female children. BALB/cByJ Cohort 1 (n = 6 per treatment group; 6–7 weeks of age) was tested for acute oxytocin effects on sociability in the three-chambered choice task (Fig. 1). Two separate BALB/cByJ cohorts were tested following sub-chronic oxytocin treatment: Cohort 2 (n = 12 per treatment group; 8–9 weeks of age at time of testing) and Cohort 3 (n = 15–18 per treatment group; 7–8 weeks of age at time of testing) were each tested in the three-chambered choice task approximately 24 h following the final dose of vehicle or oxytocin (Fig. 1).

2.3.2. C57/J model

Male and female mice (15–16 of each sex per treatment group; 7–8 weeks of age at time of testing) were used to evaluate the effects of sub-chronic oxytocin treatment on both social preference and repetitive behavior. Both male and female C57/J mice were included in this study, because each displays profound ASD-relevant phenotypes (Ryan et al., 2010), and were available from in-house breeding. For the sociability study, all mice were tested approximately 24 h following the sub-chronic oxytocin regimen. In order to evaluate possible long-term effects of sub-chronic oxytocin exposure, half of the mice were re-tested for sociability 1 week after the final injection (C57/J Cohort 1), and the remaining mice were re-tested 2 weeks after the final injection (C57/J Cohort 2) (Fig. 1). Test groups were balanced as much as possible for treatment and sex. C57/J Cohort 1 (6–8 per treatment group per sex) was further assessed for repetitive behavior 3–4 h following the sociability test at the 24-h and 1-week time points (Fig. 1).

C57/J Cohort 3 (11 males and 10 females; 4–6 months in age) was evaluated for acute oxytocin effects on repetitive behavior using a crossover study design. This crossover design was executed such that half of the mice received vehicle while the other half received oxytocin for the first test, then one week later, the reverse treatments were given for a second test. Thus, each mouse was given two tests, one with vehicle pretreatment and one with oxytocin pretreatment, with one week between the tests. In order to determine the acute effects of oxytocin on general activity, C57/J Cohort 4 (8 males and 8 females; 4–5 months in age) was tested in an open field test, using the same crossover design.

2.4. Three-chambered choice test

Social approach was assessed using an automated three-chambered box (Moy et al., 2007; Nadler et al., 2004) with retractable doorways in each dividing wall to allow entry into each chamber. Entry and time spent in each chamber of the social test box were measured by photocells embedded in each doorway. The choice test had two 10-min phases. The first phase was habituation—the test mouse was first placed in the middle chamber, then the doorways were opened to the side chambers (empty) in order to allow 10 min of free exploration. The second phase was sociability—the habituation period, the test mouse was enclosed in the center compartment of the social test box, then an unfamiliar stranger (a sex-matched C57Bl/6J adult mouse) was placed in a wire cage in one side chamber, while an empty wire cage was placed in the other side. The stranger mouse’s location was alternated between the left and right chambers of the social test box across subjects. The doors were then reopened, and the subject was allowed to explore the entire social test box for 10 min. Measures were taken of the time spent in each chamber and number of entries into each chamber by the automated testing system. In addition, a human observer scored time spent sniffing each wire cage, using previously described software (Johns et al., 1998).

2.5. Repetitive behavior in C57/J

To assess repetitive behavior, each subject was placed into a clean home cage and video recorded for 20 min (acute regimen) or 30 min (sub-chronic regimen). The videos were scored for motor stereotypy, grooming, and locomotion using Observer XT (Noldus Information Technology, Leesburg, VA). Two types of motor stereotypy were scored: jackhammer jumping and backflipping, as previously defined (Ryan et al., 2010). These behaviors were selected as the predominant forms exhibited by C57/J (Ryan et al., 2010). Locomotion was coded during bouts of ambulation in which the animal took at least 3 steps (with not more than 1 s between steps). The total numbers of jumps and backflips were combined for the motor stereotypy score, while grooming and locomotion were scored for duration.

2.6. Open field activity

Activity was assessed immediately following oxytocin or vehicle treatment in a 2-h test in a photocell-equipped automated open field (41 cm × 41 cm × 30 cm; Versamax System, AccuScan Instruments, Columbus, OH). Parameters included total distance and time spent in the center region of the chamber. Activity chambers were contained inside sound-attenuating boxes, equipped with ceiling lights and fans.

2.7. Statistical analysis

Data were analyzed using StatView software (SAS, Cary, NC). For the BALB/cByJ model, groups were compared with repeated measures analysis of variance (ANOVA), with factors treatment, cohort group (for the sub-chronic regimen), and side of social test box. For the C57/J model, data from the social task were analyzed with repeated measures ANOVAs, with factors treatment, sex, time of test, and side of social test box. Separate repeated measures ANOVAs were conducted for each sex to determine oxytocin effects on sociability in male and female mice. Within-treatment repeated measures ANOVAs were used to determine social preference. Activity data were analyzed with repeated measures ANOVAs, with factors treatment, sex, and time (5-min intervals across a 2-h test). For all comparisons, significance was set at p < 0.05.

![Fig. 2](image-url). Lack of prosocial effects of oxytocin with acute treatment in male BALB/cByJ mice. Oxytocin (1.0 mg/kg) was administered 50 min before evaluating social approach in the three-chambered choice test. Data shown are means (± SEM) for 6 mice per treatment group.
3. Results

3.1. Oxytocin effects in the BALB/cByJ model

We previously reported low sociability in adolescent male BALB/cByJ mice (Moy et al., 2007). Considering the established connection between oxytocin and social behavior, we predicted that oxytocin would rescue this deficit in sociability. Surprisingly, we found that acute treatment with oxytocin failed to induce significant social preference (Fig. 2A) or increase exploration (Fig. 2B) in BALB/cByJ Cohort 1. Because acute oxytocin treatment lacked prosocial efficacy, and other behavioral studies have shown beneficial effects of repeated oxytocin administration (Bowen et al., 2011; Cushing and Carter, 2000), we next tested a sub-chronic oxytocin regimen. Following a sub-chronic regimen, two cohorts of mice (BALB/cByJ Cohorts 2 and 3) treated with oxytocin demonstrated a significant preference for social proximity in a three-chambered choice task, conducted 24 h following the final dose of oxytocin (Fig. 3). A repeated measures ANOVA on time spent in each side chamber by the two cohort groups revealed a highly significant main effect of side \( F(1,53) = 7.72, p = 0.0075 \), and a treatment \( \times \) side interaction that approached significance \( F(1,53) = 3.34, p = 0.0731 \) (Fig. 3A and B). Oxytocin also led to a significant preference for sniffing directed toward the cage containing the stranger mouse, versus the empty wire cage, in both cohort groups [within-treatment comparisons following significant main effect of side, \( F(1,51) = 8.61, p = 0.005 \), and treatment \( \times \) side interaction, \( F(1,51) = 4.59, p = 0.037 \) (Fig. 3C and D). Mice given sub-chronic exposure to oxytocin showed a small increase in number of entries during the test [treatment \( \times \) side interaction, \( F(1,53) = 4.81, p = 0.0327 \)].

![Graphs showing results of oxytocin treatment](image)

Fig. 3. Prosocial effects of oxytocin with sub-chronic treatment in male BALB/cByJ mice. The sub-chronic regimen consisted of four doses of either vehicle or oxytocin (1.0 mg/kg) across an 8–9 day period, with at least 48 h between each IP injection. Subjects were tested for sociability in the three-chambered choice test 24 h following the final dose. \( N = 12–18 \) per group. Sniffing data are missing from two mice in Cohort 2 due to experimenter error. \( * p < 0.05 \), within-group comparison.
although post-hoc comparisons were not significant (Fig. 3E and F). No significant effects of cohort were found for any measure.

3.2. Prosocial oxytocin effects in the C58/J model

Previous work in our laboratory has shown that both male and female C58/J mice exhibit social deficits, as well as overt repetitive behavior (Moy et al., 2008; Ryan et al., 2010). Because the acute oxytocin treatment did not have significant prosocial effects in the BALB/cByJ model, we only tested C58/J mice with the sub-chronic regimen. In contrast to our findings in BALB/cByJ, sub-chronic treatment with oxytocin in C58/J did not reverse lack of social preference 24 h following the final drug dose (Fig. 4). However, one study has shown that prosocial effects of repeated oxytocin administration can be observed up to 13 days post-treatment (Bowen et al., 2011). Thus, C58/J mice were given a second social approach test, with half of the mice retested 1 week after sub-chronic oxytocin treatment (C58/J Cohort 1), and half of the mice retested 2 weeks after treatment (C58/J Cohort 2). Strikingly, significant prosocial oxytocin effects emerged in these follow-up tests [within-treatment comparisons following significant main effect of side, $F(1,56) = 11.96$, $p = 0.001$; treatment × side interaction, $F(1,56) = 7.19$, $p = 0.0096$; and main effect of sex, $F(1,56) = 4.03$, $p = 0.0497$; no significant effect of week]. Notably, there were no effects of retest (week of testing) on side preference in the vehicle treatment groups.

Separate repeated measures ANOVAs were conducted for the male and female groups to determine whether the prosocial efficacy of oxytocin was dependent upon sex. In the male mice, significant sociability was observed in the oxytocin-treated group retested at the 2-week, but not the 1-week, time point [main effect of side, $F(1,28) = 4.98$, $p = 0.0339$; and main effect of week, $F(1,28) = 6.59$, $p = 0.0159$] (Fig. 4A). In contrast, strong preference for spending time in the side with the stranger mouse was observed in the oxytocin-treated female groups at both time points [main effect of side, $F(1,28) = 7.05$, $p = 0.0129$; and treatment × side interaction, $F(1,28) = 8.21$, $p = 0.0078$; no significant effect of week] (Fig. 4B).

We have previously found that the measure of time spent sniffing the wire cages is not as robust an index for social deficits as...
time spent in each side chamber (Moy et al., 2008; Ryan et al., 2010). In the present study, repeated measures ANOVAs did not identify any significant treatment effects on sniffing in either the male or female groups (Fig. 5). However, it is notable that none of the male mice treated with vehicle demonstrated significant preference for sniffing at the stranger cage, while the oxytocin-treated male mice had overt sniffing preference for the social stimulus, albeit only at the 1-week time point (post-hoc tests following main effect of side, \(F(1,28) = 13.65, p = 0.0009\)) (Fig. 5A). In contrast, both the vehicle and oxytocin groups of female mice showed significant social preference 24 h after the last dose of the drug regimen (main effect of side, \(F(1,30) = 14.46, p = 0.0007\)) (Fig. 5B). At the 1-week time point, only the oxytocin-treated female group still demonstrated sniffing preference for the stranger cage (main effect of side, \(F(1,28) = 11.9, p = 0.0018\)).

Lastly, there was a significant effect of retest on the numbers of entries, indicating that the amount of exploration in the social approach test changed with acclimation to the task (main effect of test, \(F(1,55) = 106.57, p < 0.0001\)). However, the sub-chronic oxytocin regimen did not have any effects on this measure (Fig. 6), suggesting that the increased sociability was not due to a general increase in activity during the test.

3.3. Oxytocin and repetitive behavior in the C58/J model

In addition to social and communication deficits, the C58/J strain provides a model of abnormal repetitive behavior, relevant to the core diagnostic indicators for autism (Moy et al., 2008; Ryan et al., 2010). In the present study, the effects of both acute (C58/J Cohort 3) and sub-chronic (C58/J Cohort 1) oxytocin treatment were evaluated against motor stereotypy (backflipping and repeated jumping), a lower-order form of repetitive behavior (Fig. 7). Because no significant effects of sex were determined for stereotypy following either dosing regimen, data for male and female mice were combined. As shown in Fig. 7A, an acute single-dose of oxytocin (1.0 mg/kg) decreased levels of repetitive behavior, with significant effects emerging in the last 10 min of the recording session (post-hoc comparisons following main effect of treatment, \(F(1,15) = 11.26, p = 0.0043\); and time, \(F(1,15) = 11.54, p = 0.004\)). This dose also decreased locomotion across the first and second halves of the recording session (main effect of treatment, \(F(1,15) = 19.41, p = 0.0005\); and time, \(F(1,15) = 9.35, p = 0.008\)) (Fig. 7B). However, levels of grooming were increased by oxytocin (main effect of treatment, \(F(1,15) = 9.01, p = 0.009\)), indicating that the neuropeptide did not induce general decreases in all behaviors (Fig. 7C). Sub-chronic treatment with oxytocin did not have any persistent effects on motor stereotypy, locomotion, or grooming in the C58/J mice (Fig. 7D–F).

Although the results from the acute regimen showed that oxytocin could significantly reduce aberrant repetitive behavior, the concomitant decrease in locomotion indicated that acute oxytocin might also have sedative-like effects. Therefore, the effects of oxytocin on general activity levels were examined in C58/J Cohort 4 (Fig. 8). Because repeated measures ANOVAs did not reveal significant effects of sex on measures from the activity test, data from male and female mice were combined. As shown in Fig. 8A, there were no significant effects of oxytocin on locomotion in an open field test across a 2-h session. Furthermore, oxytocin did not increase time spent in the center regions, suggesting the neuropeptide did not have anxiolytic-like effects in C58/J (Fig. 8B).

4. Discussion

This study provided the first evidence that peripherally administered oxytocin could reverse the social deficits exhibited by two mouse models with face validity to core ASD symptoms (i.e. BALB/cByJ and C58/J mice). We also observed that exogenous oxytocin could attenuate motor stereotypy in C58/J mice, at a dose that did not induce statistically significant hypoactivity in an open field test. Importantly, the ability of oxytocin to influence these ASD-like behaviors was critically dependent on the dosage regimen (i.e. sub-chronic but not acute oxytocin could improve social deficits, and vice versa for repetitive behavior in C58/J). Our preclinical findings complement clinical studies that demonstrate the beneficial effects of oxytocin in ASD subjects, and demonstrate the importance of treatment regimen, genotype, and sex in modulating oxytocin efficacy.

To date, most clinical studies have only tested acute single-dose oxytocin treatment in ASDs. For example, Hollander and colleagues found that oxytocin infusion improved social cognition and reduced repetitive behavior in ASD subjects (Hollander et al., 2007, 2003). Two other studies determined that acute intranasal oxytocin improved emotion recognition in young ASD subjects (ages 12–19), and led to increased eye gaze and more appropriate social behavior.
in high-functioning ASD subjects (Andari et al., 2010; Guastella et al., 2010). More recently, a 6-week randomized controlled trial of twice daily intranasal oxytocin in adults with ASD demonstrated efficacy on social perception and quality of life, and a trend for improvement in lower-order repetitive behavior (Anagnostou et al., 2012). Although this longer-term study showed that daily oxytocin is well tolerated and has therapeutic potential, the treatment did not have efficacy in the primary outcome measures of social cognition/function or higher-order repetitive behavior. Interestingly, clinical studies in schizophrenia (another disorder characterized by social deficits) found improvement in symptoms, including social cognition, after 2–3 weeks of daily intranasal oxytocin administration (Feifel et al., 2010; Pedersen et al., 2011). Overall, these clinical studies support oxytocin as a promising intervention, but further work is necessary to determine optimal treatment regimens and limiting factors for therapeutic efficacy. Considering the genetic heterogeneity in the human population and the differential prosocial efficacy of oxytocin treatment in BALB/cByJ and C58/J, genetic background is likely to be an important factor in modulating oxytocin response in individuals with ASD.

In the C58/J model, the sub-chronic oxytocin regimen induced prosocial effects that emerged 1–2 weeks following treatment, dependent on sex. In particular, significant sociability emerged 2 weeks post-treatment in male C58/J mice, but was observed at the 1-week and 2-week post-treatment time points in female C58/J mice. These relatively long-term effects of sub-chronic oxytocin on social behavior are consistent with findings from Bowen and colleagues showing that 10 days of once-daily oxytocin (1 mg/kg, IP) modestly improved sociability in rats after a 13-day washout period (Bowen et al., 2011). Although the neurobiology underlying the prosocial effects of sub-chronic oxytocin treatment remains to be elucidated, one contributing mechanism may be the up-regulation of the endogenous oxytocin system within the hypothalamus (e.g. increased oxytocin receptor gene expression and oxytocin secretion) with repeated exposures (Bowen et al., 2011). Another study has suggested that strong, chronic stimulation of the oxytocin system promotes the reversible structural plasticity/remodeling of oxytocinergic neurons and their associated glial cells in adult hypothalamus, leading to altered function and increased oxytocin secretion (Theodosis, 2002). Moreover, ovarian hormones stimulate hypothalamic oxytocin and oxytocin receptor expression, and enhance the electrical activity of oxytocin neurons (Armstrong et al., 2002; Bale et al., 1995; Coirini et al., 1992; de Kloet et al., 1986; Israel and Poulain, 2000; Miller et al., 1989; Patisaul et al., 2003), which may account for the higher efficacy of exogenous oxytocin in female versus male C58/J mice. The sexually dimorphic effects might also be related to sex-specific dependence on either the oxytocinergic or vasopressinergic systems, as seen in prairie voles (Cushing and Carter, 2000; Insel and Hulihan, 1995; Yamamoto et al., 2004). Taken together, these observations suggest that repeated oxytocin administration primes the oxytocin system to become more sensitive to endogenous oxytocin signaling. Because deficiencies in the oxytocin pathway have been associated with ASDs, sensitization of the oxytocin system may improve sociability in autistic people.
Considering the lack of drug therapies to ameliorate the core symptoms of ASDs, the oxytocin receptor is an attractive target, particularly for addressing the profound social deficits observed in autism. Yet, how the oxytocin system regulates social behavior is poorly understood, perhaps because this system can influence and be influenced by other neurochemical systems. For example, serotonergic receptors and glutamate receptors regulate oxytocin release (Busnardo et al., 2012; Jørgensen et al., 2003; Pampillo et al., 2001; Saydoff et al., 1991). It is notable that the few drugs that exhibit prosocial efficacy in mouse models of social deficits directly or indirectly target the serotonergic system (e.g. MDMA, buspirone, and fluoxetine) (Chadman, 2011; Gould et al., 2011; Thompson et al., 2007) and the glutamatergic system (e.g. d-serine, MP-10, papaverine, GRN-529, and AMPAKINES) (Grauer et al., 2009; Jacome et al., 2011; Labrie et al., 2008; Silverman et al., 2013, 2012b). Thus, one could speculate that an underlying mechanism for the prosocial effects of these agents is the modulation of oxytocin secretion. Conversely, oxytocin itself has been shown to influence several neurochemical systems, including the serotonergic, glutamatergic, dopaminergic, and GABAergic systems in multiple brain regions (e.g. hypothalamus, amygdala, and hippocampus) (Brussaard et al., 1996; Eaton et al., 2012; Melis et al., 2009; Ninan, 2011; Rosenfeld et al., 2011; Sala et al., 2011; Succu et al., 2011; Theodosis et al., 2006; Yoshida et al., 2009). Therefore, oxytocin treatment may stimulate a feed-forward loop through the modulation of these neurochemical systems that provide feedback input to the oxytocinergic system, which could contribute to prosocial efficacy.

In contrast to the findings on social approach, we did not observe any sexually dimorphic effects of oxytocin administration on repetitive behavior in the C58/J model. For both male and female C58/J mice, abnormal repetitive behavior was decreased by acute, but not sub-chronic, treatment with oxytocin. It is possible that the dose of oxytocin utilized in the sub-chronic regimen was not optimal for persistent effects on repetitive behavior. Other studies examining oxytocin effects in animal models have reported bell-shaped dose response curves, with higher doses of oxytocin exhibiting less efficacy than more moderate doses (Arletti and Bertolini, 1987; Kovács et al., 1985). Further, the repetitive behavior analysis after sub-chronic oxytocin treatment was conducted at the 24-h and 1-week time points, while the strongest prosocial oxytocin effects were observed at the 2-week time point. Evaluation of repetitive behavior at later time points could reveal the emergence of oxytocin treatment effects. Although our finding of decreased motor stereotypy following acute oxytocin treatment is in line with one clinical study in adults with autism or Asperger’s syndrome (Hollander et al., 2003), an important caveat is possible effects on activity, especially sedative-like action (Uvnäs-Moberg et al., 1994). In the present study, acute oxytocin led to a significant decrease in locomotion and an increase in grooming during the test for repetitive behavior, which could have confounded drug effects on motor stereotypy. While the results from the open field test imply that the acute effects of oxytocin on motor stereotypy were not simply due to hypoactivity or anxiolytic-like effects, we observed substantial variability in these measures and a possible trend for reduced locomotion during multiple time intervals. Further research will be necessary to clarify the effects of oxytocin treatment on repetitive behavior in the C58/J model, including an evaluation of dose—response.

In conclusion, sub-chronic oxytocin treatment reverses sociability deficits in the BALB/cByJ and C58/J mouse models of ASD-relevant phenotypes. These inbred mouse strains provide an attractive translational platform for screening drugs targeting the oxytocin signaling pathway and for investigating mechanisms underpinning the efficacy of oxytocin against core ASD symptoms. Our ongoing studies include testing the dose-dependence and longer-term persistence of oxytocin effects on social and repetitive behavior. Using these models, future studies analyzing the molecular and neurobiological changes in response to oxytocin treatment could provide important insights into social behavior and new avenues for drug discovery in ASDs and other disorders characterized by impaired social function.

Acknowledgments

Support for these studies was provided by the Department of Defense (AR1002312P1, AR1002312P2, and AR1002312P3) and the National Institute of Child Health & Human Development (P30 HD03110). Brian L. Teng was funded by an Autism Speaks Translational Postdoctoral Fellowship (#7952).

References


